A Vision for Change (2006). Report of the Expert Group on Mental health Policy. Government Publication Office: Dublin.Google Scholar

Barnes, T, Shingleton-Smith, A, Paton, C (2009). Antipsychotic long-acting injections: prescribing practice in the UK. The British Journal of Psychiatry 195, s37–s42.CrossRefGoogle Scholar

Baldessarini, R, Leahy, L, AArcona, S, Gause, D, Zhang, W, Hennen, J (2007). Patterns of psychotropic drug prescription for U.S. patients with diagnoses of bipolar disorders. Psychiatric Services 58, 85–91.Google Scholar

Blanco, C, Laje, G, Olfson, M, Marcus, S, Pincus, H (2002). Trends in the treatment of bipolar disorder by outpatient psychiatrists. American Journal of Psychiatry 159, 1005–1010.Google Scholar

British Medical Association & Royal Pharmaceutical Society of Great Britain (2005). British National Formulary, 50th edn. BMA & Royal Pharmaceutical Society of Great Britain: London.Google Scholar

Brown, S (1997). Excess mortality of schizophrenia. A meta-analysis. British Journal of Psychiatry 171, 502–508.Google Scholar

Brown, S, Kim, M, Mitchell, C, Inskip, H (2010). Twenty-five year mortality of a community cohort with schizophrenia. British Journal of Psychiatry 196, 116–121.Google Scholar

Clarke, AF, Holden, NL (1987). The persistence of prescribing habits: a survey and follow-up of prescribing to chronic hospitals in–patients. The British Journal of Psychiatry 150, 88–91.Google Scholar

Connolly, M, Kelly, C (2005). Lifestyle and physical health in schizophrenia. Advances in Psychiatric Treatment 11, 125–132.CrossRefGoogle Scholar

Connolly, A, Rogers, P, Taylor, D (2007). Antipsychotic prescribing quality and ethnicity – a study of hospitalised patients in south east London. Journal of Psychopharmacology 21, 191–197.Google Scholar

Correll, C, Rummel-Klugr, C, Corves, C, Kane, J, Leucht, S (2009). Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomised controlled trials. Schizophrenia Bulletin 35, 443–457.CrossRefGoogle Scholar

Dunbar, GC, Perra, MH, Jenner, FA (1989). Patterns of benzodiazepine use in Great Britain as measured by a general population survey. The British Journal of Psychiatry 155, 836–841.Google Scholar

Essock, S, Covell, N, Leckman-Westin, E, Lieberman, J, Sederer, L, Kealey, E, Finnerty, M and members of the Scientific Committee (2009). Identifying clinically questionable psychotropic prescribing practices for Medicaid recipients in New York State. Psychiatric Services 60, 1595–1602.Google Scholar

Essock, SM, Schooler, NR, Stroup, TS, McEvoy, J, Rojas, I, Jackson, C, Covell, N, The Schizophrenia Trials Network (2011). Effectiveness of switching from antipsychotic polypharmacy to monotherapy. American Journal of Psychiatry 168, 702–708.Google Scholar

Finnerty, S (2009). An audit of benzodiazepine and hypnotic prescribing in Irish in-patient psychiatric units. Irish Psychiatrist 10, 238–240.Google Scholar

Finnerty, S (2011). An audit of antipsychotic prescribing in Irish in-patient psychiatric units. Irish Psychiatrist 12, 26–27.Google Scholar

Fisher, CE, Cohen, C, Forest, L, Schweizer, T, Wasylenki, D (2011). Psychotropic medication use in Canadian long-term patients referred for psychogeriatric consultation. Canadian Geriatrics Journal 14, 73–77.Google Scholar

Grech, P, Taylor, D (2012). Long-term antipsychotic polypharmacy: how does it start, and why does it continue? Therapeutic Advances in Psychopharmacology 2, 5–11.Google Scholar

Hallahan, BP, Murray, IT, McDonald, C (2009). Benzodiazepine and hypnotic prescribing in an acute adult psychiatric in-patient unit. Psychiatric Bulletin 33, 12–14.Google Scholar

Harrington, M, Paton, C, Okocha, C, Duffett, R, Sensky, T (2002). The results of a multi-centre audit of the prescribing of antipsychotic drugs for in-patients in the UK. Psychiatric Bulletin 26, 414–418.Google Scholar

Howes, OD, Vergunst, F, Gee, S, McGuire, P, Kapur, S, Taylor, D (2012). Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to Clozapine initiation. The British Journal of Psychiatry 201, 481–485.CrossRefGoogle ScholarPubMed

Jorm, AF, Grayson, D, Creasy, H, Waite, L, Broe, G (2000). Long-term benzodiazepine use by elderly people living in the community. Australian and New Zealand Journal of Public Health 24, 7–10.Google Scholar

Joukamaa, M, Heliovaara, M, Knekt, P, Aromaa, A, Raitasalo, R, Lehtinen, V (2006). Schizophrenia, neuroleptic medication and mortality. The British Journal of Psychiatry 188, 122–127.Google Scholar

Kirby, M, Denihan, A, Bruce, I, Radic, A, Coakley, D, Lawlor, B (1999). Benzodiazepine use among the elderly in the community. International Journal of Geriatric Psychiatry 14, 280–284.Google Scholar

Kogut, SJ, Yam, F, Dufresene, R (2005). Prescribing of antipsychotic medication in a Medicaid population: use of polytherapy and off-label dosages. Journal of Managed Care Pharmacy 11, 17–24.Google Scholar

Mental Health Act (2001). Government of Ireland (2001) Mental Health Act. Dublin: Stationery Office.Google Scholar

National Institute for Clinical Excellence (2010). The NICE Guideline on core interventions in the treatment and management of schizophrenia in adults in primary and secondary care. Guideline No 82, NICE: London.Google Scholar

Noir, T (2008). High-dose and combination antipsychotic prescribing in a high security hospital. The British Journal of Psychiatry.Google Scholar

Patrick, V, Schleifer, S, Nurenberg, J, Gill, K (2006). An initiative to curtail the use of antipsychotic polypharmacy in a state psychiatric hospital. Psychiatric Services 57, 21–23.Google Scholar

Paton, C, Barnes, T, Cavanagh, MR, Taylor, D, Lelliott, P, POMH-UK Project Team (2008). High-dose and combination antipsychotic prescribing in acute adult wards in the UK: the challenges posed by P.R.N. prescribing. The British Journal of Psychiatry 192, 435–439.Google Scholar

Petitjean, S, Ladewig, D, Meier, C, Amrein, R, Wiesbeck, G (2007). Benzodiazepine prescribing to the Swiss adult population: results from a national survey of community pharmacies. International Clinical Psychopharmacology 22, 292–298.Google Scholar

Planning for the Future (1984). The Psychiatric Services – Planning for the Future. Report of a Study Group on the Development of the Psychiatric Services. Stationery Office: Dublin.Google Scholar

Royal College of Psychiatrists (2006). Consensus statement on high dose antipsychotic medication. Council Report CR 138, Royal College of Psychiatrists.Google Scholar

Royal College of Psychiatrists (2012). National Audit of Schizophrenia Recommendations. Royal College of Psychiatrists: London.Google Scholar

Ryan, MCM, Collins, P, Thakore, JH (2003). Impaired fasting glucose tolerance in first episode, drug naïve patients with schizophrenia. American Journal of Psychiatry 160, 284–289.Google Scholar

Summers, J, Brown, KW (1998). Benzodiazepine prescribing in a psychiatric hospital. Psychiatric Bulletin 22, 480–483.Google Scholar

Taylor, D, Paton, C, Kapur, S (editors) (2012). Maudsley Prescribing Guidelines in Psychiatry, 11th edn. Wiley-Blackwell.Google Scholar

Tiihonen, J, Lonnqvist, J, Wahlbeck, K, et al. (2009). 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN 11 study). Lancet 374, 620–627.Google Scholar

Waddington, JL, Joussef, HA, Kinsella, A (1998). Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. The British Journal of Psychiatry 173, 325–329.Google Scholar